环状 RNA (circRNA) 能够影响乳腺癌 (BC) 的发展。然而，circFKBP8（也称为 hsa_circ_0000915）在 BC 中的作用和潜在机制仍然很大程度上未知。使用定量实时聚合酶链反应 (qRT-PCR)、蛋白质印迹和免疫组织化学 (IHC) 检测进行表达分析。通过评估体外细胞增殖、迁移能力、侵袭和干性来确定对细胞功能表型的影响。通过 RNA Pull-down、双荧光素酶报告基因和 RNA 免疫沉淀 (RIP) 测定检查 microRNA (miR)-432-5p 和 circFKBP8 或 E2F 转录因子 7 (E2F7) 之间的关系。异种移植试验用于鉴定 circFKBP8 在体内的功能。CircFKBP8 在 BC 组织和细胞中呈高水平存在。 circFKBP8 高表达与 BC 患者较差的总生存期相关。 CircFKBP8 抑制可抑制 BC 细胞的体外增殖、迁移能力、侵袭和干性。 CircFKBP8 抑制可阻断体内异种移植肿瘤的生长。从机制上讲，circFKBP8 作为 miR-432-5p 海绵来调节 E2F7 表达。 CircFKBP8通过miR-432-5p调节BC细胞恶性行为，而miR-432-5p通过E2F7影响这些细胞表型。我们的观察证明，circFKBP8通过miR-432-5p/E2F7级联促进BC细胞恶性表型，提供了一种有前途的治疗方法BC 的预后目标。© 2024。作者。

Circular RNAs (circRNAs) are capable of affecting breast cancer (BC) development. However, the role and underneath mechanism of circFKBP8 (also known as hsa_circ_0000915) in BC remain largely unknown.Expression analyses were performed using quantitative real-time polymerase chain reaction (qRT-PCR), western blot, and immunohistochemistry (IHC) assays. Effects on cell functional phenotypes were determined by assessing cell proliferation, migratory capacity, invasion, and stemness in vitro. The relationship between microRNA (miR)-432-5p and circFKBP8 or E2F transcription factor 7 (E2F7) was examined by RNA pull-down, dual-luciferase reporter, and RNA immunoprecipitation (RIP) assays. Xenograft assays were used to identify the function of circFKBP8 in vivo.CircFKBP8 was presented at high levels in BC tissues and cells. High circFKBP8 expression was associated with worse overall survival in BC patients. CircFKBP8 suppression inhibited BC cell proliferation, migratory capacity, invasion and stemness in vitro. CircFKBP8 suppression blocked xenograft tumor growth in vivo. Mechanistically, circFKBP8 functioned as a miR-432-5p sponge to modulate E2F7 expression. CircFKBP8 modulated BC cell malignant behaviors by miR-432-5p, and miR-432-5p affected these cell phenotypes through E2F7.Our observations prove that circFKBP8 promotes BC malignant phenotypes through the miR-432-5p/E2F7 cascade, offering a promising therapeutic and prognostic target for BC.© 2024. The Author(s).